<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920358</url>
  </required_header>
  <id_info>
    <org_study_id>CIP EMEA 18-01</org_study_id>
    <nct_id>NCT03920358</nct_id>
  </id_info>
  <brief_title>FRED/ FRED Jr/ FRED X Intracranial Aneurysm Treatment Study</brief_title>
  <acronym>FRITS</acronym>
  <official_title>FRED/ FRED Jr/ FRED X Intracranial Aneurysm Treatment Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Microvention-Terumo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Microvention-Terumo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multicenter, observational evaluation of the safety and efficacy of the FRED®&#xD;
      device in the treatment of intracranial aneurysms&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center observational study. Treatment and follow-up visits will be performed&#xD;
      as per standard of care. The purpose of this study is to demonstrate that use of the FRED/&#xD;
      FRED Jr/ FRED X Embolic device in intracranial aneurysm treatment is safe and effective when&#xD;
      assessed at 6, 12 months and yearly up to 5 years post procedure.&#xD;
&#xD;
      150 patients will be enrolled over an 15-month recruitment period. All patients will be&#xD;
      followed for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 10, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete aneurysm occlusion without associated stenosis of the parent artery (&gt; 50%)</measure>
    <time_frame>12 months</time_frame>
    <description>Complete occlusion (Raymond Scale grade I) without stenosis of the parent artery.&#xD;
Raymond scale definition: Grade I= complete occlusion of aneurysm, Grade II= Residual neck, Grade III= Residual aneurysm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morbidity Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Patients with mRS&gt;2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Deaths within 6 months after treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FRED, FRED Jr and FRED X</intervention_name>
    <description>Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm</description>
    <other_name>Flow Re-Direction Endoluminal Device</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are at least 18 years of age presenting with an unruptured or recanalized&#xD;
        intracranial aneurysm requiring endovascular treatment. Those eligible to be treated with&#xD;
        FRED/ FRED Jr/ FRED X will be enrolled after having signed an informed consent form.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient older than 18 years old&#xD;
&#xD;
          2. Patient harboring a non-acutely ruptured intracranial aneurysm within the last 30 days&#xD;
             of presentation:&#xD;
&#xD;
               -  for which use of FRED, FRED Jr or FRED X has been deemed appropriate&#xD;
&#xD;
               -  being the only aneurysm to require treatment within the next 12 months&#xD;
&#xD;
               -  and optionally previously treated by surgery (clipping) or with an intrasaccular&#xD;
                  device: aneurysm recanalized&#xD;
&#xD;
          3. Patient with a modified Rankin Scale (mRS) ≤ 2&#xD;
&#xD;
          4. Patient has received information about data collection and has signed and dated an&#xD;
             Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has suffered from an ICH within the 30 days prior to the procedure.&#xD;
&#xD;
          2. The aneurysm to be treated is associated with a cAVM&#xD;
&#xD;
          3. The aneurysm to be treated is in the posterior circulation&#xD;
&#xD;
          4. The aneurysm to be treated has a stenosis of its parent artery &gt;50%&#xD;
&#xD;
          5. Patient has another aneurysm previously treated with a stent or a flow diverter&#xD;
&#xD;
               -  on the same parent vessel at any time&#xD;
&#xD;
               -  on a different parent vessel, less than 3 months prior to the procedure&#xD;
                  (previously-implanted stents in the non-index proximal carotid are acceptable)&#xD;
&#xD;
          6. Patient with whom anticoagulant, antiplatelet or thrombolytic drugs are&#xD;
             contra-indicated or test performed regarding AP medication administered is not&#xD;
             efficient for the patient&#xD;
&#xD;
          7. Patient with known hypersensitivity to contrast products or nickel titanium, not&#xD;
             treatable&#xD;
&#xD;
          8. Pregnancy or child breastfeeding&#xD;
&#xD;
          9. Patient unable or unlikely to complete required follow up&#xD;
&#xD;
         10. Patient has severe or fatal comorbidity or a life expectancy of less than 1 year&#xD;
&#xD;
         11. Treatment with a flow diverter other than FRED/ FRED Jr/ FRED X or in addition to&#xD;
             FRED/ FRED Jr/ FRED X is planned&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnd Dörfler, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence Bousquet, PhD</last_name>
    <phone>+33139217746</phone>
    <email>laurence.bousquet@microvention.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Boyer</last_name>
    <phone>+33139217746</phone>
    <email>patricia.boyer@microvention.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnd Dörfler, Prof. Dr. med.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

